SoonerCare does not cover Wegovy or Zepbound for weight loss

SoonerCare does not cover drugs used mainly to treat obesity. It covers Wegovy (injection and tablets) only to lower the risk of major cardiovascular events in members with established heart disease, the Wegovy injection only for MASH, and Zepbound only for moderate to severe obstructive sleep apnea, each with prior authorization; none is approved for weight loss alone.12345

SoonerCare approves Wegovy and Zepbound only through indication-specific prior authorization criteria, with separate requests for each dose during titration (8 weeks at a time) and 1-year approvals at the maintenance dose.234910

• Wegovy injection or tablets, cardiovascular risk reduction: age 45 or older, established cardiovascular disease with a previous heart attack, previous stroke or symptomatic peripheral arterial disease, a BMI of 27 or more, no type 1 or type 2 diabetes, an A1c under 6.5%, current guideline-directed therapy for cardiovascular disease, and use with diet and exercise documented in office notes.
• Wegovy injection, MASH: age 18 or older, noncirrhotic MASH with stage F2 or F3 fibrosis confirmed by FibroScan, an ELF test or a liver biopsy, no other chronic liver disease, no type 1 or type 2 diabetes, use with diet and exercise, and prescribed by or with a gastroenterologist or hepatologist.
• Zepbound, obstructive sleep apnea: age 18 or older, moderate to severe OSA with an apnea-hypopnea index of 15 or more on a sleep study, a BMI of 30 or more, no central or mixed sleep apnea, no type 1 or type 2 diabetes, an A1c under 6.5%, and use with diet and exercise; pens and KwikPens are preferred over vials.
• No other GLP-1 at the same time, and the drug is stopped if the member cannot tolerate at least the 1.7 mg Wegovy or 5 mg Zepbound maintenance dose.
• Maintenance approvals need documentation that the member tolerates the dose, has not developed diabetes, and continues a reduced-calorie diet and more physical activity.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults 45 or older with established cardiovascular disease and a BMI of 27 or more, without diabetes (injection and tablets): Covered with prior authorization2
• Wegovy (injection), noncirrhotic MASH with stage F2 or F3 liver fibrosis, without diabetes (injection): Covered with prior authorization3
• Zepbound, moderate to severe obstructive sleep apnea in adults with obesity (BMI of 30 or more), without diabetes: Covered with prior authorization4

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no OHCA announcement that Oklahoma has joined.11

HealthChoice's prescription benefits for state employees are administered by CVS Caremark. Its 2025 health plan handbook lists "certain weight loss drugs" among drug exclusions without naming them, and we found no public HealthChoice document that states its GLP-1 weight-loss policy.121314

Pharmacy benefit: CVS Caremark (prescription benefits); HealthChoice is run by the Employees Group Insurance Division of the Office of Management and Enterprise Services (OMES EGID).

Marketplace (ACA) plans: Oklahoma's essential health benefits benchmark plan, a Blue Cross Blue Shield of Oklahoma small-group Blue Options Gold PPO, excludes drugs prescribed for the treatment of obesity or for weight loss.1819

On SoonerCare's anti-diabetic tier chart no GLP-1 is in Tier 1. Trulicity and brand Victoza are the lowest-tier GLP-1s (Tier 2, which needs a type 2 diabetes diagnosis and a metformin trial), Ozempic and Rybelsus are Tier 3, and Mounjaro needs special prior authorization. Higher tiers need a documented type 2 diabetes diagnosis, current and goal A1c, and either stable use of the drug or failed trials of the lower-tiered GLP-1s.678

In 2025, SoonerCare paid for 80,833 GLP-1 prescriptions, $82.8 million before rebates: 20 per 1,000 residents, against 32 across the states and DC, 34th of 51.67 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 26 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4243333429372232

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2930312237383940413635
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.242622

In 2024, Medicare Part D drug plans paid for 349,885 GLP-1 claims from prescribers in Oklahoma, $415.9 million in total drug cost.68

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.72 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Oklahoma on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7374 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by Oklahoma’s board of pharmacy or attorney general on their own sites.20

The FDA’s register lists 2 outsourcing facilities (503B) in Oklahoma, as of November 6, 2026; 1 show no inspection date and 1 were issued a Form 483.69